Wall Street Zen Downgrades Intellia Therapeutics (NASDAQ:NTLA) to Strong Sell

Intellia Therapeutics (NASDAQ:NTLA) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday.

Other equities research analysts also recently issued research reports about the company. Sanford C. Bernstein lifted their target price on Intellia Therapeutics from $13.00 to $17.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Leerink Partners set a $35.00 price target on shares of Intellia Therapeutics in a research report on Monday, April 27th. Robert W. Baird lifted their price objective on shares of Intellia Therapeutics from $7.00 to $13.00 and gave the stock a “neutral” rating in a research note on Monday, April 27th. Citigroup restated a “market outperform” rating on shares of Intellia Therapeutics in a research report on Monday, June 15th. Finally, New Street Research set a $25.00 target price on shares of Intellia Therapeutics in a report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, eight have given a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $20.85.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $11.94 on Friday. The firm has a market cap of $1.67 billion, a P/E ratio of -3.55 and a beta of 1.81. Intellia Therapeutics has a 1-year low of $7.95 and a 1-year high of $28.25. The business’s 50 day moving average is $13.65 and its 200-day moving average is $13.48.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, hitting the consensus estimate of ($0.80). The business had revenue of $7.66 million during the quarter, compared to analysts’ expectations of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The firm’s revenue for the quarter was down 46.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.98) EPS. Analysts forecast that Intellia Therapeutics will post -3.18 EPS for the current year.

Insiders Place Their Bets

In related news, CAO Michael P. Dube sold 2,641 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the transaction, the chief accounting officer owned 66,886 shares of the company’s stock, valued at $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the sale, the executive vice president directly owned 156,286 shares of the company’s stock, valued at $2,813,148. This represents a 2.91% decrease in their position. The SEC filing for this sale provides additional information. 3.50% of the stock is currently owned by company insiders.

Institutional Trading of Intellia Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Intellia Therapeutics during the second quarter valued at approximately $260,721,000. ARK Investment Management LLC increased its stake in shares of Intellia Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after purchasing an additional 2,288,146 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Intellia Therapeutics by 17.8% during the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock worth $116,960,000 after buying an additional 1,965,181 shares in the last quarter. State Street Corp raised its holdings in shares of Intellia Therapeutics by 29.1% during the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock worth $57,705,000 after buying an additional 1,447,967 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Intellia Therapeutics by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock worth $24,243,000 after buying an additional 107,333 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics News Roundup

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Evercore ISI upgraded Intellia Therapeutics, citing its “nex-z hypothesis.” The upgrade suggests the firm sees potential for the program to create meaningful long-term value and improve the company’s outlook. Intellia upgraded at Evercore ISI on nex-z hypothesis
• Positive Sentiment: Brookline Capital Markets modestly improved its fourth-quarter 2026 EPS forecast to a loss of $0.41 from a loss of $0.47. Its longer-term model still projects a return to profitability beginning in 2027, which may support the investment case if clinical development succeeds. Brookline Capital Markets estimates
• Neutral Sentiment: Bank of America Securities maintained a Hold rating, indicating that it does not currently see a strong enough catalyst to recommend buying or selling the shares. Bank of America Securities remains a Hold on Intellia Therapeutics
• Neutral Sentiment: Recent analysis highlighted narrowing losses but continued heavy research-and-development spending. Intellia’s latest quarterly revenue also trailed estimates, underscoring that the company remains dependent on clinical progress rather than current operating revenue. Will Intellia’s narrowing losses and heavy R&D spend shift its risk reward narrative?
• Negative Sentiment: Brookline reduced its EPS forecasts for the second and third quarters of 2026 and lowered the full-year estimate to a $2.84 loss from a $2.76 loss. More significantly, it sharply cut projected earnings for 2027–2030, signaling substantially lower expectations for Intellia’s eventual commercial opportunity.
• Negative Sentiment: Wall Street Zen downgraded NTLA to Strong Sell. Together with the lower long-term estimates and BofA’s Hold rating, the call reflects substantial uncertainty around clinical execution, cash usage and the timing of profitability. Intellia lowered to Strong Sell rating

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.